Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0
|
作者：
Lio, Peter [1 ]
Eichenfield, Lawrence F. [2 ,3 ,4 ]
Marcoux, Danielle [5 ]
Lee, Wan-Ju [6 ]
Teixeira, Henrique D. [6 ]
Raymundo, Eliza M. [6 ]
Gamelli, Amy E. [6 ]
Grada, Ayman [6 ]
Hu, Xiaofei [6 ]
Irvine, Alan D. [7 ,8 ]
机构：
[1] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Evanston, IL USA
[2] Univ Calif San Diego, Dept Dermatol, San Diego, CA USA
[3] Univ Calif San Diego, Dept Pediat, San Diego, CA USA
[4] Rady Childrens Hosp San Diego, San Diego, CA USA
[5] Univ Montreal, St Justine Univ Hosp Ctr, Div Dermatol, Dept Pediat, Montreal, PQ, Canada
[6] AbbVie Inc, N Chicago, IL USA
[7] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[8] Dermatol Childrens Hlth Ireland, Dublin, Ireland
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42065
引用
收藏
页码：AB178 / AB178
页数：1
相关论文
共 50 条
  • [41] Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)
    Simpson, Eric L.
    Costanzo, Antonio
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Chu, Alvina D.
    Wu, Tianshuang
    Eyerich, Kilian
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II30 - II31
  • [42] ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES
    Prajapatil, Vimal
    Simpson, Eric L.
    Thyssen, Jacob P.
    Chovatiya, Raj
    Lane, Michael
    Teixeira, Henrique
    Calimlim, Brian
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 33 - 33
  • [43] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Reich, Kristian
    Teixeira, Henrique D.
    de Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Werfel, Thomas
    Zeng, Jiewei
    Huang, Xiaohong
    Hu, Xiaofei
    Hendrickson, Barbara A.
    Ladizinski, Barry
    Chu, Alvina D.
    Silverberg, Jonathan I.
    LANCET, 2021, 397 (10290): : 2169 - 2181
  • [44] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (MeasureUp 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (vol 397, pg 2151, 2021)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Katoh, Norito
    LANCET, 2021, 397 (10290): : 2150 - 2150
  • [45] DISCONTINUATION OF TOPICAL CORTICOSTEROIDS IN UPADACITINIB-TREATED PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS FROM THE AD UP PHASE 3 TRIAL
    Reich, Kristian
    Boguniewicz, Mark
    Kabashima, Kenji
    Barbarot, Sebastien
    Girolomoni, Giampiero
    Mendes-Bastos, Pedro
    Gamelli, Amy
    Liu, Yingyi
    Teixeira, Henrique
    Armstrong, April
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 61 - 61
  • [46] Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis
    Yosipovitch, Gil
    de Bruin-Weller, Marjolein
    Wiseman, Marni
    Elberling, Jesper
    Gutermuth, Jan
    Pierce, Evangeline
    Montmayeur, Sonia
    Ding, Yuxin
    Yang, Emily
    Chisolm, Sarah
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB61 - AB61
  • [47] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the pivotal phase III, randomized, double-blind, placebo-controlled AD Up study
    Reich, K.
    Teixeira, H. D.
    De Bruin-Weller, M.
    Bieber, T.
    Soong, W.
    Kabashima, K.
    Werfel, T.
    Zeng, J.
    Huang, X.
    Hu, X.
    Ladizinski, B.
    Chu, A. D.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E59 - E60
  • [48] Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial
    Paller, Amy S.
    Weidinger, Stephan
    Cork, Michael J.
    Marcoux, Danielle
    Katoh, Norito
    Zhang, Haixin
    Rossi, Ana B.
    Shumel, Brad
    Zhang, Annie
    Prescilla, Randy
    Chao, Jingdong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB141 - AB141
  • [49] Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS
    Silverberg, Jonathan I.
    Yosipovitch, Gil
    Simpson, Eric L.
    Kim, Brian S.
    Wu, Jashin J.
    Eckert, Laurent
    Guillemin, Isabelle
    Chen, Zhen
    Ardeleanu, Marius
    Bansal, Ashish
    Kaur, Mandeep
    Rossi, Ana B.
    Graham, Neil M. H.
    Patel, Naimish
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : 1328 - 1336
  • [50] BIMEKIZUMAB DEMONSTRATES SUSTAINED IMPROVEMENT IN QUALITY OF LIFE UP TO WEEK 52 IN PATIENTS ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
    McKay, Neil D.
    Bennett, Alexander
    Goodson, Nicola
    Fleurinck, Carmen
    de la Loge, Christine
    Massow, Ute
    Taieb, Vanessa
    Marzo-Ortega, Helena
    Gaffney, Karl
    RHEUMATOLOGY, 2024, 63 : I157 - I158
12345